Exploring Capivasertib: A New AKT Inhibitor for Targeted Cancer Treatment

One of the latest and most promising AKT inhibitors for use in cancer treatment appears to have promising potential, particularly when the underlying issue is the dysregulation of the PI3K/AKT1/mTOR pathway. The PI3K/AKT/mTOR pathway is essential for various cellular functions, such as growth, metabolism, survival, and proliferation, and it has been found to be disrupted in numerous cancers, particularly breast cancer. Preclinical studies have highlighted the anticancer properties of capivasertib, leading to further investigations in clinical trials. This phase 3 CAPItello-291 trial demonstrated the effectiveness of capivasertib when combined with fulvestrant for patients with hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2 − ) advanced breast cancer. This combination therapy enhanced progression-free survival in patients, especially those with alterations in the PI3K/AKT1 pathway. Data are also available on the combination with paclitaxel, indicating tolerability and clinical benefits. General pharmacokinetic assessments suggest favorable absorption and distribution profiles of capivasertib, enabling flexible dosing schedules. However, significant concerns remain regarding side effects, particularly diarrhea, hyperglycemia, and rash. Nevertheless, current clinical trials are optimizing the administration of capivasertib for intermittent dosing while exploring its overall effectiveness against various cancers, including BRCA-mutated cancers, due to its interaction with PARP inhibitors. The use of capivasertib is a crucial advancement in targeted cancer therapy, offering renewed optimism for patients facing challenging malignancies. Future research should focus on refining treatment protocols, minimizing toxic effects, and identifying predictive biomarkers to improve patient outcomes.